Curie.Bio’s Post

Download the poster titled 'Modelling Epithelial Barrier Function and Mucociliary Clearance Using Small Airway Epithelium Cells' https://lnkd.in/e4KpGhk7 #SAEC #Pulmonarytoxicology

Learn how Cullinan Oncology transitioned from R&D to the clinic and is now aiming to become a fully integrated commercial-stage biotech company. On this episode of Business of Biotech, CEO Nadim Ahmed shares his story and that of the company's drug discovery efforts, which have yielded multimodal candidates spanning a range of cancer indications. https://cytiva.link/6d9ma #Biotech #BusinessOfBiotech #DrugDiscovery

There’s no better time to start your data capture of in vivo oncology, in vitro, and biomarker studies with CrownLink™. Our customer portal is designed to fit your needs with benefits of capturing and monitoring study data without the hassle of a manual process. Experience the benefits of a streamlined workflow today. Register for free https://bit.ly/3tOGXRo #InVitro #InVivo #Oncology #Biomarkers #Biotech #Bioscience

DYK Shasqi's CAPAC technology can be used to localize RLTs ⚡ to the tumor? A major pain point for mAb-based radioconjugates is the prolonged exposure and low tumor-to-blood ratio, which causes dose-limiting toxicities. To overcome this, Shasqi separates the radionuclide from the targeting component and reunites the two at the tumor using click chemistry. This enables optimal clearance of the RLT and reduces non-specific toxicities. Shasqi's Jesse McFarland and Tri-Hung Nguyen recently presented a poster on this apprpach at the Gordon Research Conferences, 'Exploring the Power of Radioimmunobiology Via Switching the Radionuclides, Ligands and Immunotargets' in beautiful Maine. Learn more: https://bit.ly/46lz190 #RLTs

Check out Neo’s lite paper demonstrating the prevelance of RET fusions across 18 tumor types #rwd #precisionmedicine #precisiononcology

I recently had the pleasure of attending the Gordon Research Conference on Targeted Radionuclides in Oncology with my colleague, Tri-Hung Nguyen. It was exciting to hear recent developments in the field of radioligand therapies (RLTs) and experience the discussions on key topics for the discovery of next gen therapeutics, including choice of radionuclide and targeting modality. While RLTs clearly have the potential to deliver powerful anti-tumor efficacy to patients, the burning question on everyone's mind is how the toxicities can be derisked through preclinical and Phase 0 studies, including biodistribution and ADME analysis. The future of RLTs is bright!

In the Winter Issue of the European Biotechnology - Life Science and Industry Magazine (EBM), CSO Andreas Pahl outlines in an interview with Georg Kääb the advantages of Heidelberg Pharma's many years of experience in the development of new customized and highly effective cancer drugs based on ADC technologies. View the full article "Cancer: Hit it with your best shot": https://t1p.de/ko635 #cancertherapies #amanitin #adc

With over 25 years of experience in research, technology, and biotech, Noelle Gaskill of Mirati Therapeutics approaches the challenges of DCTs with a comprehensive perspective, prioritizing listening to research sites. Get a sneak peek into her #ACRP2024 session, where she shares tactical insights from collaborating with thought-leaders, regulators, and sites, aiming to launch a hybrid DCT interventional oncology trial this year. Learn more about Noelle's session in Anaheim > https://bit.ly/3T5ahLX #GoForIt #GoForEducation #ClinicalTrials #ClinicalResearch #ClinicalTrialDesign #DCT #DecentralizedClinicalTrials

Curious to learn more about Antibody-Drug Conjugates (ADCs)? Listen to the latest episode of the Biotech Matters Podcast by Bluestar BioAdvisors, LLC as my colleagues Erin Olsen and Jeff Fineberg discuss some of the lessons learned from approved ADCs and where we think things are headed. Do not hesitate to reach out with any questions! #biotech #pharma #oncology #cancer #ADC

Antibody-drug conjugates are among the most promising drug classes in oncology. In our recent on-demand webinar, CAS experts explore the latest trends in #ADC innovation and the complications of understanding the #IP landscape in this area. https://ow.ly/fa6m50QexaP